ACTG announcement
CHAPEL HILL, N.C., April 21, 2026 — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the HoT study (Menopausal Hormone Therapy for Women Living with HIV, also known as A5424), an essential new study with the potential to significantly expand the body of knowledge around menopause among women living with HIV. HoT is a phase 4, randomized, double-blind, placebo-controlled clinical trial that will evaluate the safety and efficacy of hormone therapy (estradiol gel with or without oral progesterone) compared to placebo for women living with HIV who are in the late menopausal transition or early post-menopause and experiencing moderate to severe vasomotor symptoms (commonly known as hot flashes and flushes and night sweats).
Compared to the general population, research has demonstrated that women living with HIV experience more frequent and severe vasomotor symptoms, which, importantly, correlates with increased depression and anxiety, worse cognitive function and quality of life, and interference with daily life activities, including work.
Read the full announcement here.
Source : GLOBE NEWSWIRE
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.